Pharmadrug (TSE:PHRX)
:PHRX
Want to see TSE:PHRX full AI Analyst Report?
PHRX Stock Chart & Stats
C$0.02
<C$0.01(33.33%)
At close: 4:00 PM EST
C$0.02
<C$0.01(33.33%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.03
Previous CloseN/A
Volume5.00K
Average Volume (3M)101.80K
Market Cap
C$1.34M
Enterprise ValueC$2.64M
Total Cash (Recent Filing)C$387.71K
Total Debt (Recent Filing)C$1.61M
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding134,214,390
10 Day Avg. Volume83,723
30 Day Avg. Volume101,798
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory And Partnership FocusA strategic emphasis on regulatory pathways and evaluating assets/partnerships is a durable business-model lever. Successful regulatory progress or distribution partnerships can enable commercialization, de-risk R&D spend, and convert pipeline value into recurring revenue over the medium term.
Lower Absolute Debt Vs Prior PeakDebt having declined from its 2019 peak improves financial flexibility relative to that high-water mark. Lower absolute leverage reduces interest and covenant pressure, extending operational runway and giving management more options to pursue partnerships or reorganize without acute debt overhang.
Improved Cash Burn Trend Vs Earlier YearsA demonstrable improvement in cash burn versus the 2021–2022 period indicates better cost control or smaller cash needs. If sustained, this structural improvement lengthens runway, reduces reliance on frequent financing, and allows more deliberate strategic decisions over the next several quarters.
Bears Say
Revenue Collapse To Near ZeroSustained near-zero revenue across multiple years is a profound structural weakness: without recurring sales, the company cannot generate internal funding for R&D or commercialization. This undermines long-term viability and forces dependence on external financing or asset disposals.
Negative Shareholder Equity (solvency Risk)Negative equity signals solvency strain and reduces creditor and investor confidence. It constrains access to conventional financing, may trigger covenants or creditor actions, and limits the company's ability to invest or pursue partnerships, posing a persistent structural constraint.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business cannot self-fund operations or growth. Long-term reliance on external funding dilutes shareholders or increases leverage, reducing resilience to shocks and making sustained product development or commercialization harder.
Pharmadrug News
PHRX FAQ
What was Pharmadrug’s price range in the past 12 months?
Pharmadrug lowest stock price was <C$0.01 and its highest was C$0.03 in the past 12 months.
What is Pharmadrug’s market cap?
Pharmadrug’s market cap is C$1.34M.
When is Pharmadrug’s upcoming earnings report date?
Pharmadrug’s upcoming earnings report date is Aug 21, 2026 which is in 64 days.
How were Pharmadrug’s earnings last quarter?
Currently, no data Available
Is Pharmadrug overvalued?
According to Wall Street analysts Pharmadrug’s price is currently Overvalued.
Does Pharmadrug pay dividends?
Pharmadrug does not currently pay dividends.
What is Pharmadrug’s EPS estimate?
Pharmadrug’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmadrug have?
Pharmadrug has 134,214,390 shares outstanding.
What happened to Pharmadrug’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmadrug?
Currently, no hedge funds are holding shares in TSE:PHRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmadrug
Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived from nature. The company also manages the import and supply of medical cannabis to pharmacies across Germany and the broader European Union. Additionally, it operates Super Smart, an entity focused on advancing the application of functional and psilocybin mushrooms, and engages in studies to reformulate established natural medicines. Pharmadrug maintains key research collaborations, including an agreement with the University of Michigan to explore the potential role of N, N-dimethyltryptamine (DMT) in various states of consciousness. It has also partnered with the Southwest Research Institute for the manufacturing of cepharanthine and entered into a clinical trial agreement with Johns Hopkins University to compare the acute and enduring psychological and neural effects of DMT against another potent active molecule. The company adopted its current name in October 2019, having previously operated as Aura Health Inc.
Technical Analysis
Mountain Valley MD
―
Revive Therapeutics
―
InnoCan Pharma
―
Ramm Pharma
―
Aion Therapeutic Inc
―
Options Prices
Currently, No data available
---